See All Slides - tctmd.com

Slides

Presentation THT 2023

FDA Guidance on Meaningful Representation in Clinical Trials

Presenter: Bram Zuckerman

March 20, 2023

Presentation THT 2023

Devices for ADHF: The DRI2P2S Framework

Presenter: Hannah Rosenblum

March 20, 2023

Presentation THT 2023

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

Presenter: Graham Nichol

March 20, 2023

Presentation THT 2023

Now is Not Soon Enough: Why Improving Patient Diversity in HF Trials is a Key Priority

Presenter: Harriette Van Spall

March 20, 2023

Presentation THT 2023

Medical Therapies of DHF and the Concept of "Diuretic Resistance"

Presenter: W. H. Wilson Tang

March 20, 2023

Presentation THT 2023

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

Mystery Case 2

Presenter: Jennifer Ho

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Mauro Moscucci

March 20, 2023

Presentation THT 2023

How Do We Improve Advanced Heart Failure Outcomes in ACHD? ACTION Learning Network

Presenter: Ari Cedars

March 20, 2023

Advertisement

Slides

FDA Guidance on Meaningful Representation in Clinical Trials

Devices for ADHF: The DRI2P2S Framework

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

Now is Not Soon Enough: Why Improving Patient Diversity in HF Trials is a Key Priority

Medical Therapies of DHF and the Concept of "Diuretic Resistance"

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Mystery Case 2

FDA Introduction

How Do We Improve Advanced Heart Failure Outcomes in ACHD? ACTION Learning Network

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content